In the realm of contemporary medical challenges, intervertebral disc (IVD) degeneration leading to low back pain stands out as a prevalent issue affecting many individuals. Despite advancements in diagnostic and treatment modalities, the focus has predominantly been on pain management rather than addressing the root cause of disc degeneration. In this context, the exploration of strategies aimed at regenerating or repairing the IVD structure has gained significant attention, with mesenchymal stromal cell (MSC) therapy emerging as a promising avenue for research and clinical application.
MSCs offer a range of advantages for therapeutic use, including their availability from various adult tissues, multilineage differentiation potential, and immunomodulatory properties. While preclinical studies have shown promise for MSCs in IVD regeneration, translating these findings into clinical practice poses challenges, particularly in assessing outcomes due to the lack of direct histological evidence in living human patients. Magnetic resonance imaging (MRI) serves as the primary tool for evaluating disc regeneration indirectly by monitoring changes in disc hydration and size, reflecting alterations in proteoglycan content.
In the pursuit of a translational approach to assess the efficacy of autologous MSC-based IVD therapy, a clinical model utilizing dogs with naturally occurring IVD degeneration was employed. This canine model offers advantages such as closely mimicking human clinical trial conditions, natural disease development, comparable size to humans, and similar evaluation methods to human medicine. Building on previous studies, a novel approach utilizing collagen microcarriers as a scaffold for delivering MSCs into degenerated discs was investigated to enhance cell viability, provide mechanical support, and localize growth factors for promoting desired differentiation conditions.
The comprehensive translational clinical study had a three-fold objective: evaluating microcarriers for supporting canine MSC chondrogenic differentiation in vitro, assessing biomechanical properties of microcarriers in canine lumbosacral segments ex vivo, and testing safety and efficacy of intradiscal MSC-microcarrier injection in clinically affected dogs. Mechanical testing on cadaveric lumbosacral segments demonstrated the feasibility of microcarrier injection without compromising disc integrity, while stiffness evaluation highlighted the potential of microcarriers to restore disc height and orientation post-injection.
Twenty client-owned dogs diagnosed with degenerative lumbosacral stenosis underwent intradiscal injection of MSC-microcarrier suspensions as part of the clinical study. Clinical assessment and owner questionnaires revealed improvements in pain and disability scores post-operatively across all treatment groups. However, MRI follow-up at 10 months did not show significant changes in the Pfirrmann score of degenerated discs, indicating a lack of visible disc regeneration. Notably, two dogs developed transient lumbosacral pain post-injection, attributed to the formation of Schmorl’s nodes, highlighting a potential complication associated with the therapy.
The study findings underscore the challenges in achieving disc regeneration through MSC therapy in naturally degenerated discs, despite promising clinical improvements in pain and disability scores. The discrepancy between clinical outcomes and MRI findings emphasizes the complexity of translating preclinical success to clinical efficacy. The study’s limitations, including the inability to objectively quantify pain and disability in dogs compared to human studies, underscore the need for further research to refine therapeutic approaches for IVD degeneration.
In conclusion, the study sheds light on the intricacies of canine lumbosacral intervertebral disc treatment using cell therapy and collagen microcarriers. While the results point to promising clinical outcomes, the absence of visible disc regeneration on MRI underscores the need for continued research to enhance the effectiveness of MSC-based therapies in addressing IVD degeneration. The study’s insights contribute to the ongoing quest for innovative and effective strategies to combat this prevalent medical issue.
Key Takeaways:
– Mesenchymal stromal cells (MSCs) show promise for intervertebral disc (IVD) regeneration but face challenges in clinical translation.
– Canine models offer a translational approach for evaluating MSC therapy in IVD degeneration, providing insights into clinical outcomes and potential complications.
– Collagen microcarriers serve as a promising scaffold for delivering MSCs into degenerated discs, enhancing cell viability and promoting differentiation.
– Clinical improvements in pain and disability scores post-injection highlight the therapeutic potential of MSC-microcarrier therapy despite the lack of visible disc regeneration on MRI.
– Further research is needed to refine therapeutic approaches for IVD degeneration, addressing challenges in achieving successful regeneration outcomes.
Tags: cell therapy, clinical trials, cell therapies
Read more on pmc.ncbi.nlm.nih.gov